ABOUT JAHR

The Journal of AIDS and HIV Research (JAHR) is published monthly (one volume per year) by Academic Journals.

Journal of AIDS and HIV Research (JAHR) is an open access journal that provides rapid publication (monthly) of articles in all areas of the subject like the implications for gender-based HIV and AIDS prevention interventions, Sputum cellularity in pulmonary tuberculosis, Comparative tolerability and efficacy of stavudine 30 mg versus stavudine 40 mg in patients on combination antiretroviral therapy, HIV and sexual risk behaviours amongst intravenous drug users etc.

The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in JAHR are peer reviewed

Contact Us

Editorial Office: jahr@academicjournals.org

Help Desk: helpdesk@academicjournals.org

Website: http://www.academicjournals.org/journal/JAHR

Submit manuscript online http://ms.academicjournals.me/
Editors

Prof. Bechan Sharma,
Department of Biochemistry,
University of Allahabad,
Allahabad,
India.

Prof. Ruta Dubakiene,
Vilnius University,
Lithuania.

Prof. William Nuhu Ogala,
Ahmadu Bello University Teaching Hospital,
Zaria, Nigeria.

Dr. John E. Lewis,
University of Miami,
Miller School of Medicine,
1120 NW 14th Street
Suite #1474 (D21)
Miami, FL 33136
USA.
Editorial Board

Dr. Arun Kumar,
Manipal College of Medical Sciences,
India.

Dr. Manal Fouad Ismail,
Faculty of Pharmacy,
Cairo University,
Egypt.

Dr. Esrat Gharaei Gathabadi,
Mazandaran University of Medical Sciences, Sari
Faculty of Pharmacy,
Iran.

Dr. P. Aparanji,
Department of Biochemistry,
Andhra University Visakhapatnam,
India.

Dr. Amzad Hossain,
Atomic Energy Centre,
GPO Box 164, Ramna,
Dhaka-1000,
Bangladesh.

Prof. Irvin Mpofu,
University of Namibia,
Namibia.

Dr. Rajiv Nehra,
Muzaffarnagar Medical College,
India.

Dr. Marion W. Mutugi,
Jomo Kenyatta University of Agriculture and Technology,
Kenya.

Dr. Emmanuel Nwabueze Aguwa,
Department of Community Medicine,
College of Medicine,
University of Nigeria,
Enugu Campus,
Nigeria.

Dr. William A. Zule,
RTI International,
USA.

Dr. M. Abhilash,
The Oxford College Of Engineering,
Bommanahalli, Hosur Road, Bangalore 560068,
India.

Dr. Fukai Bao,
Kunming Medical University,
China.

Dr. Baligh Ramzi Yehia,
University of Pennsylvania School of Medicine,
Philadelphia, PA,
USA.

Dr. Khandokar Mohammad Istiaq,
University of Dhaka,
Dhaka-1000,
Bangladesh.

Dr. Aamir Shahzad,
Max F. Perutz Laboratories,
University of Vienna,
Vienna Bio center, A-1030 Vienna,
Austria.

Dr. Subarna Ganguli,
Pharmacy college in Kolkata ,
West Bengal,
India.

Dr. Mehmet Kale,
Dept. of Virology,
Mehmet Akif Ersoy University,
Faculty of Veterinary Medicine,
Turkey.

Mr. Shakeel Ahmed Ibne Mahmood
Bangladesh AIDS Prevention Society, BAPS, Bangladesh
Youth Wing, National AIDS Committee,
Bangladesh.

Dr. Adewumi, Moses Olubusuyi,
Department of Virology,
College of Medicine,
University College Hospital,
University of Ibadan,
Ibadan,
Nigeria.

Dr. Theodoros Eleftheriadis,
General Hospital of Serres,
Serres,
Greece.

Dr. Keertan Dheda,
University of Cape Town,
South Africa.
ARTICLES

Evaluation of HIV post-exposure prophylaxis (PEP) in a tertiary health institution in south-eastern Nigeria  
Isah Abdul Muminu, Igboeli Nneka Uchenna, Adibe Maxwell Ugochukwu and Ukwe Chinwe Victoria  
108

Evaluation of prevention of mother-to-child transmission (PMTCT) of HIV in a tertiary health institution in south-eastern Nigeria  
Isah Abdul Muminu, Igboeli Nneka Uchenna, Adibe, Maxwell Ogochukwu and Ukwe Chinwe Victoria  
114
Full Length Research Paper

Evaluation of HIV post-exposure prophylaxis (PEP) in a tertiary health institution in south-eastern Nigeria

Isah Abdul Muminu*, Igboeli Nneka Uchenna, Adibe Maxwell Ugochukwu and Ukwe Chinwe Victoria

Department of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria.

Received 1 April, 2016; Accepted 16 May, 2016

This study aimed to evaluate the implementation of HIV post-exposure prophylaxis (PEP) guidelines and determine its clinical outcome in a PEPFAR (APIN-CDC) Clinic in south-eastern Nigeria from 2008 to 2012. It was a retrospective review of data of patients who accessed HIV PEP services from the clinic. Data on demographic and clinical characteristics of patients were retrieved from the database of the clinic and analyzed. Descriptive statistics and Chi-square test were applied to analyzed data at significance level of $p<0.05$. The result showed that thirty three (33) individuals were enrolled into PEP during the period. Thirty-one (31; 93.94%) were due to occupational exposure, while two (2; 6.06%) were due to non-occupational exposure. AZT+3TC 23 (69.70%), AZT+3TC+LPV/r 9 (27.27%) and AZT+3TC+ATV/r+RTV 1 (3.03%) were the ARVs used. The nature of exposure did not significantly determine the choice of the ARV. The study concludes that APIN/CDC Clinic, UNTH Enugu substantially followed recommendations of standard guidelines in HIV PEP management, but the absence of follow-up test results for majority of the enrollees was an impediment to any general statement on its clinical outcome.

Key words: HIV, post-exposure prophylaxis, Nigeria.

INTRODUCTION

Post-exposure prophylaxis (PEP) in human immunodeficiency virus (HIV) generally refers to the medical response given to prevent the transmission of blood-borne pathogens after a potential exposure (WHO, 2007). In relation to HIV, it refers to a set of services provided to manage specific aspect of exposure to HIV and prevent the transmission of HIV in cases where exposure occurs (WHO, 2007) after occupational injuries (Department of Health, 2004) or sexual exposure (Fisher et al., 2006). The set of services in PEP include provision of first aid, counseling, assessment of risk of exposure to the infection, HIV testing and depending on the outcome of the exposure assessment, the prescription of a 28-day course of antiretroviral drugs, with appropriate support and follow-up is instituted (WHO, 2007). Two nucleoside-analogue reverse-transcriptase inhibitors (NRTIs) with or
without a protease inhibitor (PI) are used for a total of four weeks post exposure, commencing not later than 72 h after the exposure. It is believed that PEP reduces the likelihood of infection after such an exposure by at least 80%, with evidences from animal model data and case control studies (Erhabor et al., 2007; Date and Fisher, 2007). PEP was commenced in the early 1990s for occupational exposures such as needle stick or cuts and has since been expanded to include all other means of exposure to HIV infection (WHO, 2007). It is noteworthy that 99.7% of needle sticks do not result in actual transmission of HIV infection (Becker, 1989).

The objectives of this study were to evaluate the implementation of post-exposure prophylaxis (PEP) guideline and determine its clinical outcome in a PEPFAR (APIN-CDC) Clinic in south-eastern Nigeria from 2008 to 2012.

MATERIALS AND METHODS

Study design

This study was a single-site descriptive hospital-based study in which retrospective data were abstracted from the clinic’s database.

Study setting

The UNTH PEPFAR/APIN Plus Clinic situated at the permanent site of UNTH at Ituku Ozalla, Enugu was the centre used for this study.

Study size

Relevant data of all the patients that met the eligibility criteria of the study were used.

Eligibility criteria:
The inclusion criteria for the study were:
1. The data of individuals who accessed the PEP service completely at UNTH
2. The data of individuals who gave consent for the use of their information in studies.

Ethical consideration

Health Research Ethics Committee of the UNTH and the PEPFAR IRB, Harvard School of Public Health gave approval for the study. The researchers ensured strict confidentiality in the conduction of this study.

Source and method of data collection

The source of data for this study was the File-Maker Professional (FMPro) database of the PEPFAR/APIN Clinic, UNTH Enugu, managed and maintained daily by Data Managers. The FMPro database contained information on all patients who received treatment or care for HIV from the PEPFAR/APIN site. Such information included patients’ demographics, medical history, physical examination including WHO staging, medications, laboratory tests (CD4 count, viral load, complete blood count, liver function test, etc.), adherence information, pharmacy refill records, presence of opportunistic infections, among several others. Other information contained in the FMPro database was the number of doctors and pharmacists with whom the patients had contacts.

Variables retrieved

The data of the individuals needed from the database for this study which were abstracted include gender, age, nature of exposure, ARV regimen used and HIV antibody test results after the first, third and sixth months.

Data management and analysis

The data were abstracted from the clinic’s database and input into Microsoft Excel where they were checked. The data were then analyzed using FMPro (Version 10) and IBM – SPSS (Version 21). Descriptive statistics and Chi-square test were applied to analyze data at significance level of P<0.05. Results of the study were expressed as frequency (percentage) and mean ± SD. Data were presented as tables and charts as applicable to the collected data.

RESULTS

Demographic characteristics of PEP enrollees

The total number of patients enrolled into PEP for the period studied based on the eligibility criteria of the study was thirty three (33), distributed over the years, as is in Figure 1. Of this number, thirty-one (31; 93.94%) were due to occupational exposure, while two (2; 6.06%) were due to non-occupational exposure (both being rape cases). Fifteen (15; 45.45%) were males while eighteen (18; 54.55%) were females (Table 1).

These demographic characteristics are some of the monitoring and evaluation indicators in the PEPFAR Programme Essential Indicators (PEPFAR Outcome Prevention Sub Area 6) (Becker, 1989).

PEP characteristics of the enrollees

The result of the study indicates that the APIN-CDC Clinic UNTH, Enugu used three ART regimens for PEP patients, viz.: AZT+3TC (23; 69.70%), AZT+3TC+LPV/r (9; 27.27%) and AZT+3TC+ATV/r +RTV (1; 3.03%) (Table 2). None of the demographic characteristics significantly determined the choice of ARV (Table 3).

HIV antibody test and result

HIV antibody testing is to be conducted three times after completion of the prescribed ART regimen: the first, third and sixth months. APIN-CDC UNTH Clinic, Enugu did not perform the HIV antibody tests at the stipulated times for the PEP enrollees. The percentage of PEP-enrollees that was later enrolled into HAART (after completing the
specific regimen) for HIV infection, probably due to PEP failure was 0%.

DISCUSSION

Demographic characteristics of PEP enrollees

The study revealed that more females enrolled into the PEP programme than males, with the majority being in the youth age bracket. This result was similar to the findings of another study (Onyedum et al., 2011). Since most of the cases with reported nature of exposure were due to occupational exposure, the young age may be due to the naivety of healthcare workers beginning their practices. There were no individuals enrolled into PEP in 2008 and 2009 even though the service was available then. There was a gradual increase in the enrollment to the programme from 2010 to its peak in 2012. This development could be as a result of increased sensitization and awareness of the need for and the availability of PEP which is an important predictor of PEP enrollment (Varghese et al., 2003; Chacko and Isaac, 2007; Erhabor et al., 2007). The knowledge of most health workers on HIV PEP in third-world countries remains inadequate (Tebeje and Hailu, 2010).

Table 1. Demographic characteristics of the PEP enrollees at APIN-CDC Clinic, UNTH, Enugu (2008-2012).

<table>
<thead>
<tr>
<th>Sex</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>2 (6.06)</td>
<td>1 (3.03)</td>
<td>12 (36.36)</td>
<td>15 (45.45)</td>
</tr>
<tr>
<td>Female</td>
<td>0 (0.00)</td>
<td>1 (3.03)</td>
<td>17 (51.52)</td>
<td>18 (54.55)</td>
</tr>
<tr>
<td>Total</td>
<td>2 (6.06)</td>
<td>2 (6.06)</td>
<td>29 (87.87)</td>
<td>33 (100.0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age (Years)</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;20</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (3.03)</td>
<td>1 (3.03)</td>
</tr>
<tr>
<td>20 – 29</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>21 (63.64)</td>
<td>21 (63.64)</td>
</tr>
<tr>
<td>30 – 39</td>
<td>2 (6.06)</td>
<td>2 (6.06)</td>
<td>6 (18.18)</td>
<td>10 (30.30)</td>
</tr>
<tr>
<td>40 – 49</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (3.03)</td>
<td>1 (3.03)</td>
</tr>
<tr>
<td>≥50</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>Total</td>
<td>2 (6.06)</td>
<td>2 (6.06)</td>
<td>29 (87.87)</td>
<td>33 (100.0)</td>
</tr>
</tbody>
</table>

Mean ± SD 28.55 ± 6.87

Figure 1. Distribution of the PEP enrollees at APIN-CDC Clinic, UNTH, Enugu (2008-2012).
Table 2. PEP characteristics of the enrollees at APIN-CDC Clinic, UNTH, Enugu (2008-2012).

<table>
<thead>
<tr>
<th>Variables</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nature of Exposure</td>
<td>Occupation</td>
<td>2 (6.06)</td>
<td>1 (3.03)</td>
<td>28 (84.85)</td>
</tr>
<tr>
<td></td>
<td>Non-Occupational</td>
<td>0 (0.00)</td>
<td>1 (3.03)</td>
<td>1 (3.03)</td>
</tr>
<tr>
<td>Total</td>
<td>2 (6.06)</td>
<td>2 (6.06)</td>
<td>29 (87.88)</td>
<td>33 (100.00)</td>
</tr>
<tr>
<td>ARV Regimen Used</td>
<td>AZT+3TC</td>
<td>2 (6.06)</td>
<td>1 (3.03)</td>
<td>20 (60.60)</td>
</tr>
<tr>
<td></td>
<td>AZT+3TC+LPV/r</td>
<td>0 (0.00)</td>
<td>1 (3.03)</td>
<td>8 (24.24)</td>
</tr>
<tr>
<td></td>
<td>AZT+3TC+ATV/r +RTV</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (3.03)</td>
</tr>
<tr>
<td>Total</td>
<td>2 (6.06)</td>
<td>2 (6.06)</td>
<td>29 (87.88)</td>
<td>33 (100.00)</td>
</tr>
<tr>
<td>HIV Antibody Test Result</td>
<td>Positive</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>(1st Month)</td>
<td>Negative</td>
<td>1 (3.03)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td></td>
<td>Not Conducted</td>
<td>1 (0.00)</td>
<td>2 (6.06)</td>
<td>29 (87.88)</td>
</tr>
<tr>
<td>Total</td>
<td>2 (6.06)</td>
<td>2 (6.06)</td>
<td>29 (87.88)</td>
<td>33 (100.00)</td>
</tr>
<tr>
<td>HIV Antibody Test Result</td>
<td>Positive</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>(3rd Month)</td>
<td>Negative</td>
<td>1 (3.03)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td></td>
<td>Not Conducted</td>
<td>1 (3.03)</td>
<td>2 (6.06)</td>
<td>29 (87.88)</td>
</tr>
<tr>
<td>Total</td>
<td>2 (6.06)</td>
<td>2 (6.06)</td>
<td>29 (87.88)</td>
<td>33 (100.00)</td>
</tr>
<tr>
<td>HIV Antibody Test Result</td>
<td>Positive</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td>(6th Month)</td>
<td>Negative</td>
<td>1 (3.03)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
<tr>
<td></td>
<td>Not Conducted</td>
<td>1 (3.03)</td>
<td>2 (6.06)</td>
<td>29 (87.88)</td>
</tr>
<tr>
<td>Total</td>
<td>2 (6.06)</td>
<td>2 (6.06)</td>
<td>29 (87.88)</td>
<td>33 (100.00)</td>
</tr>
</tbody>
</table>

PEP was available in 2008 and 2009, but no enrollee.

Compliance of APIN-CDC Clinic, UNTH, Enugu PEP practice with guidelines

The World Health Organization (WHO) and International Labour Organization (ILO) produced a joint guideline on PEP to prevent HIV in 2007. The guideline posits that the standard PEP regimen should comprise two nucleoside-analogue reverse-transcriptase inhibitors, with three-drug regimens, comprising two nucleoside-analogue reverse-transcriptase inhibitors plus a boosted protease inhibitor, only considered in situations where antiretroviral therapy resistance is known or suspected (WHO, 2007). A two drug regimen is preferred to a three drug regimen because, apart from the absence of any study that shows the relative efficacy of the two regimens, the relative ease of administration (resulting potentially in better adherence, fewer side effects and lower costs) and the ease of procurement, storage and dispensing makes the former the preferred and most recommended regimen (WHO, 2007).

The Nigerian Federal Ministry of Health (FMOH)’s National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults in 2010 specified that the two drug regimen to be used in the country should contain zidovudine and lamivudine or zidovudine and abacavir or tenofovir and lamivudine or tenofovir and emtricitabine. The recommended three drug regimen in the guideline includes the addition of lopinavir with ritonavir boost or efavirenz to two NRTIs (Federal Ministry of Health, 2010). The guideline warns, however, that nevirapine should never be used in PEP due to the risk of toxicity (fatal hepatotoxicity) and efavirenz should be avoided in pregnancy or women of childbearing age due to the risk of teratogenicity, a position similar to that of WHO (2007) and Federal Ministry of Health (2010).

The APIN-CDC Clinic, UNTH, Enugu thus complied substantially with the WHO/ILO and Federal Government of Nigeria (FGN) guidelines on the selection of regimen and prescription of drugs in the selected regimens. Reviews in international online databases to evaluate the effects of HIV PEP concluded that two-drug regimens were more frequently used and had fewer incidences of adverse events as compared to three-drug regimens (Young et al., 2007).

In terms of the time of test during the period covered by PEP, both guidelines recommend that HIV antibody testing should be conducted after commencement of the therapy in the first, third and sixth months. The result of this study revealed that only one enrollee had the three post-PEP therapy HIV antibody tests conducted for.
There was no evidence to show that the other enrollees reported to the clinic for the follow-up such that the non-conduction of the tests cannot be solely blamed on the clinic. A study conducted in the same clinic vindicates the position as it showed that none of the enrollees returned to the clinic for follow-up counseling and test (Onyedum et al., 2011).

This behaviour is however in contradiction to the result of a study in San Francisco in which 75% of those enrolled returned for HIV antibody test at the sixth month follow-up (Khan et al., 2001). The difference in the setting could be the reason for the better habit. The fear of stigmatization upon knowing the result could also be responsible, more so that most of the enrollees were staff of the clinic that would not want the result of their tests known at their work place. It is thus difficult to conclude from this study whether the clinic complied (or did not comply) with the guidelines in terms of post-therapy tests on the PEP enrollees.

**Evaluation of the clinical outcome of PEP at APIN-CDC Clinic, UNTH, Enugu**

The aim of PEP in the APIN-CDC clinic, UNTH, Enugu is to prevent the transmission of HIV to persons exposed to probably HIV-infected individuals. The measure of this outcome is the enrollment of anyone PEP is prescribed into HAART. This is determined by the result of post-PEP therapy, HIV Antibody test. The tests were conducted for only one enrollee with the result being negative, showing a good outcome. A check of the database did not show the existence of any of the PEP enrollees later recruited for HAART, since the policy of the clinic was to use the same identity for an individual for PEP and HAART. The assumption was that since most of the PEP enrollees were due to occupational exposure by staff of UNTH, an enrollment to HAART within the period of the study will most probably be in the same clinic. This also showed a possible good outcome. This result should also be considered in the context that other studies have shown that PEP can reduce the risk of infection to HIV by 81% in resource rich settings (Gold and Tomkins, 2005), although the study in San Francisco revealed that there was no seroconversion in any of the enrollees (Khan et al., 2001). PEP should be seen as a cost-effective complement to existing HIV-preventive measures (Pinkerton et al., 2004), even when it is based on limited direct evidence of effect (Young et al., 2007).

**Conclusion**

APIN-CDC Clinic UNTH Enugu substantially complied with standard guidelines in ARV prescription for HIV PEP. This study however posits that the clinical outcome of PEP in the clinic could not be determined because its database had no result of the post-PEP HIV antibody test for majority of its enrollees. It is recommended that some policies should be introduced to check the issue of poor follow-up, such as the conduction of the follow-up tests at other clinics which are not directly related to the site and the introduction of a shorter duration to provide the ARVs instead of the 28 days as currently practised.
Limitations

There are some limitations to this study, in the light of which the work should be considered. The small study size is one of such limitations. The result of the clinical outcome evaluation is also limited by the lack of follow-up HIV antibody tests.

Conflict of Interests

The researchers declare that there is no conflict of interests regarding this publication.

ACKNOWLEDGEMENTS

The role of APIN (PS 001058), US Department of Health and Human Services, Health Resources and Services Administration (U51HA02522) and the Centers for Disease Control and Prevention (CDC) in managing and providing the data for this study is hereby appreciated by the researchers.

REFERENCES


Federal Ministry of Health (FMOH) (2010). National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults.


Evaluation of prevention of mother-to-child transmission (PMTCT) of HIV in a tertiary health institution in south-eastern Nigeria

Isah Abdul Muminu*, Igboeli Nneka Uchenna, Adibe, Maxwell Ogochukwu and Ukwe Chinwe Victoria

Department of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka, Enugu State, Nigeria.

Received 8 March, 2016; Accepted 18 July, 2016

Mother-to-child transmission is the highest mode of acquisition of HIV infection in children, with a 15-45% risk of an infant acquiring HIV from an infected mother without any medical intervention. The objectives of this study were to evaluate the implementation of prevention of mother-to-child transmission (PMTCT) guidelines and determine its clinical outcome in a PEPFAR Clinic in Nigeria from 2008 to 2012. A retrospective review of data of patients who accessed PMTCT from the Clinic in the University of Nigeria Teaching Hospital (UNTH), Enugu was conducted. Data were retrieved from the clinic’s database and analyzed. The result showed that three hundred and seventy-three (373) pregnant women (aged 30.22±4.88) and three hundred and sixty-seven (367) children from the pregnancies were enrolled into PMTCT. Ten (10) regimens were used for the mothers: AZT/3TC/NVP, TDF/3TC+NVP and AZT/3TC+EFV accounting for 80.00, 11.00 and 2.65%, respectively. AZT (15.80%) and NVP (84.20%) were used for the infants, 8 (2.18%) of whom tested positive for HIV. The study concluded that PEPFAR Clinic, UNTH Enugu substantially followed the guidelines in its PMTCT programme which was found to drastically reduce the transmission of HIV from mother to child.

Key words: APIN-CDC, ARVs, highly active antiretroviral therapy (HAART), HIV, prevention of mother-to-child transmission (PMTCT).

INTRODUCTION

Heterosexual relationship is responsible for the highest mode of infection of human immunodeficiency virus (HIV) in Africa (Pokharel et al., 2012). In such a relationship, women are disadvantaged, as the risk of transmitting HIV infection from men to women is higher by almost a 24 fold rate (Pokharel et al., 2012; Arulogun et al., 2007). This makes the infection increase faster in women than men especially in sub-Saharan Africa where women comprise 58% of existing HIV infections (UNAIDS, 2002a). It is estimated that approximately 5,000 women are newly infected with HIV daily out of which more than 3,000 die from acquired immune deficiency syndrome.
(AIDS) related illnesses (UNAIDS, 2002b). It therefore means that children are also at risk of acquiring the infection. In fact, out of about half a million children aged under 15 years who are infected with HIV annually, more than 90% got infected as a result of mother-to-child transmission during pregnancy, labour and delivery or breastfeeding (Arulogun et al., 2007). This is because, without intervention, there is a 15-45% risk of an infant acquiring the virus from an infected mother (Pokharel et al., 2012; De Cock et al., 2000; Hussein et al., 2011), making mother-to-child transmission the main mode of acquisition of HIV infection in children under 15 years (Arulogun et al., 2007). The estimate is 15-25% in industrialized nations and 25-45% in developing countries (Karim et al., 2002; Msellati et al., 1992). In some of the developing nations, more than 40% of all live births are HIV infected (Pokharel et al., 2012).

To achieve one of the goals of highly active antiretroviral therapy (HAART) (improving quality of life), the HIV-positive patient is given the opportunity to parent children who would be HIV free. This places a burden on the woman who is required to take some steps to ensure that there is no transmission from her to the foetus in the womb, and to the infant upon delivery, irrespective of the means of breastfeeding. The summary of the efforts is to reduce the viral load of the woman to a minimum possible level, while working for a significant increase in the CD4 count. The main goal of prevention of mother-to-child transmission (PMTCT) is thus minimizing the transmission of HIV by increasing coverage and access to its services (HAPCO, 2003). PMTCT involves a comprehensive four-pronged strategy which WHO stipulates to include HIV prevention, preventing unintended pregnancies in HIV positive women and follow-up treatment and support as well as therapeutic interventions around delivery (Ezegbe and Stephenson, 2012). The Nigerian National PMTCT programme follows these four strategies (Federal Ministry of Health, 2005). PMTCT is included in the services provided by the United States President’s Emergency Plan for AIDS Relief (PEPFAR) for HIV infected individuals. Only the therapeutic intervention aspect of PMTCT was measured in this study because PEPFAR’s main PMTCT service in Nigeria is therapeutic intervention (Ezegbe and Stephenson, 2012).

The first objective of this study was to evaluate the implementation of PMTCT standard guidelines (WHO and Federal Government of Nigeria) in a PEPFAR (APIN-CDC) Clinic in South-eastern Nigeria from 2008 to 2012. The second objective was to determine the clinical outcome of PMTCT in the Clinic.

**METHODOLOGY**

**Study design**

This study was a descriptive hospital-based study in which retrospective data were abstracted from the Clinic’s database.

**Study setting**

The UNTH PEPFAR (APIN-CDC) Clinic situated at the permanent site of UNTH at Iyoku Ozalla, Enugu State, South-eastern Nigeria was the center used for this study. The relevant data of all the patients that met the eligibility criteria of the study were used.

**Eligibility criteria**

The eligibility criteria for the study were:

1. The pregnant HIV-infected mother placed on ART accessed and completed PMTCT service solely from APIN-CDC Clinic UNTH, Enugu.
2. The infants’ PMTCT service was also solely obtained at APIN-CDC Clinic UNTH, Enugu.

**Ethical consideration**

Ethical approval was obtained from the Health Research Ethics Committee of the UNTH and the PEPFAR IRB, Harvard School of Public Health. Strict confidentiality was ensured in conducting this study.

**Data collection**

The File-Maker Professional (FMPro®) Version 10 database of the PEPFAR (APIN-CDC) Clinic, UNTH Enugu, was the source of data for this study. Information on patients who received treatment and care for HIV at the Clinic that are available on the database include patients’ demographics, medical history, physical examination including WHO staging, medications, laboratory tests (CD4 count, viral load, complete blood count, liver function test, etc.), adherence information, pharmacy refill records, presence of opportunistic infections, among several others.

The information retrieved from the database for this study were age, marital status, pre-PMTCT status, ART regimen used for PMTCT and adherence level (for the mothers); and ARV used and the result of HIV DNA-PCR and antibody tests (for the child).

**Data management and analysis**

The abstracted data were first checked for correctness. They were then analyzed with FMPro and IBM SPSS (Version 21). Descriptive statistics and Chi-square test were applied at P<0.05. The results of the study were expressed as frequency (percentage) and mean ± SD which were presented in tables and figures, as applicable.

**RESULTS**

**Demographic characteristics of the PMTCT enrollees**

Three hundred and seventy-three (373) pregnant women and three hundred and sixty-seven (367) children who resulted from the pregnancies were enrolled into the PMTCT during the period and they met the inclusion criteria of the study. Their distributions increased from 22 (5.90%) in 2008 to 136 (36.46%) in 2012 (Figure 1). Most
of the pregnant women (52.82%) did not have their marital status indicated in the database. For those indicated, 119 (31.90%) were married, with mean age of 30.22±4.88 (Table 1). The pre-PMTCT status of the pregnant women showed that 322 (86.32%) were already on HAART, while only 6 (1.61%) were not eligible for HAART prior to their enrolment (Table 1).

ART regimen used for PMTCT

Ten different ART regimens were prescribed for the pregnant mothers. Three hundred (80.43%) were given AZT/3TC/NVP, while TDF/3TC+/NVP (11.00%), AZT/3TC+EFV (2.95%), TDF/3TC+AZT+LPV/r (1.61%), 3TC/AZT (1.61%), among others were the rest (Table 2). The choice of the ART regimen was made taking into cognizance the pregnant mothers’ pre-PMTCT status (Table 3). Only NVP (309; 84.20%) and AZT (58; 15.80%) were prescribed to and administered to the infants from immediately after birth to six weeks. HIV Antibody test was not conducted for any of the infants, but HIV DNA-PCR was conducted for all after six weeks of birth (Table 4). For the HIV DNA-PCR test, 8 (2.18%) tested positive after the completion of PMTCT, while the remaining 359 (97.80%) tested negative to the virus.

DISCUSSION

Demographic characteristics of the PMTCT enrollees

The result of the study indicated that enrollment to PMTCT services increased over the years, a result that alluded to strengthened coverage overtime, possibly due to increased knowledge about the service (Hussein et al., 2011). Most of the women were young and married, similar to those of other PMTCT studies (Hussein et al., 2011; Joseph et al., 2011). A small percentage of the pregnant mothers were teenagers, indicating that teenage pregnancy remained an issue as shown in another PMTCT study (Hussein et al., 2011). Most of the enrollees were already on HAART, a predictor of improved obstetric and perinatal outcomes for HIV positive women, as compared to those who took other preventive measures during the pregnancy (Joseph et al., 2011). However, majority of the enrollees had a low adherence rate, a major problem discovered in PMTCT service which another study sought solution for Holstad et al. (2012).

Compliance with guidelines

The pre-PMTCT status of the pregnant women significantly (p<0.05) determined the ART regimens prescribed for them. Most of the regimens used at the clinic were those with proven efficacy and safety in pregnancy according to the two guidelines. All the infants were given recommended and safe ARVs. The prescribed ARVs (NVP or AZT) did not significantly determine the clinical outcome of the service in the infants. The guidelines also stipulate the conduction of HIV DNA-PCR and HIV Antibody tests after birth for all children. The Clinic complied by conducting the HIV DNA-PCR test for all the children, but it did not conduct the HIV Antibody test for any of the children. Cost has been mentioned as an impediment to the simultaneous

Figure 1. Distribution of PMTCT enrollees at APIN-CDC Clinic UNTH Enugu (2008-2012).
### Table 1. The demographic and PMTCT characteristics of the pregnant women at APIN-CDC Clinic UNTH Enugu (2008-2012).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (Years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>3 (0.80)</td>
<td>4 (1.07)</td>
</tr>
<tr>
<td>20 – 29</td>
<td>5 (1.35)</td>
<td>17 (4.46)</td>
<td>18 (4.83)</td>
<td>51 (13.67)</td>
<td>55 (14.75)</td>
<td>146 (39.14)</td>
</tr>
<tr>
<td>30 – 39</td>
<td>17 (4.46)</td>
<td>22 (5.90)</td>
<td>23 (6.17)</td>
<td>79 (21.18)</td>
<td>76 (20.38)</td>
<td>217 (58.18)</td>
</tr>
<tr>
<td>40 – 49</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
<td>0 (0.00)</td>
<td>2 (0.54)</td>
<td>2 (0.54)</td>
<td>5 (1.35)</td>
</tr>
<tr>
<td>≥50</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
</tr>
<tr>
<td>Total</td>
<td>22 (5.90)</td>
<td>41 (11.00)</td>
<td>42 (11.26)</td>
<td>132 (35.39)</td>
<td>136 (36.46)</td>
<td>373 (100.00)</td>
</tr>
<tr>
<td><strong>Marital status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>8 (2.14)</td>
<td>23 (6.17)</td>
<td>17 (4.46)</td>
<td>33 (8.85)</td>
<td>38 (10.19)</td>
<td>119 (31.90)</td>
</tr>
<tr>
<td>Separated</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>2 (0.54)</td>
<td>1 (0.27)</td>
<td>3 (0.80)</td>
</tr>
<tr>
<td>Divorced</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>2 (0.54)</td>
<td>0 (0.00)</td>
<td>2 (0.54)</td>
</tr>
<tr>
<td>Single</td>
<td>4 (1.07)</td>
<td>5 (1.35)</td>
<td>10 (2.68)</td>
<td>8 (2.14)</td>
<td>11 (2.95)</td>
<td>38 (10.19)</td>
</tr>
<tr>
<td>Widowed</td>
<td>1 (0.27)</td>
<td>3 (0.80)</td>
<td>2 (0.54)</td>
<td>3 (0.80)</td>
<td>5 (1.35)</td>
<td>14 (3.75)</td>
</tr>
<tr>
<td>Not Indicated</td>
<td>9 (2.41)</td>
<td>10 (2.68)</td>
<td>13 (3.49)</td>
<td>84 (22.52)</td>
<td>81 (21.72)</td>
<td>197 (52.82)</td>
</tr>
<tr>
<td>Total</td>
<td>22 (5.90)</td>
<td>41 (11.00)</td>
<td>42 (11.26)</td>
<td>132 (35.39)</td>
<td>136 (36.46)</td>
<td>373 (100.00)</td>
</tr>
<tr>
<td><strong>Pre-PMTCT status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Already On HAART</td>
<td>17 (4.46)</td>
<td>31 (8.31)</td>
<td>39 (10.46)</td>
<td>118 (31.64)</td>
<td>117 (31.37)</td>
<td>322 (86.32)</td>
</tr>
<tr>
<td>Commencing HAART</td>
<td>2 (0.54)</td>
<td>8 (2.14)</td>
<td>2 (0.54)</td>
<td>1 (0.27)</td>
<td>6 (1.61)</td>
<td>19 (5.09)</td>
</tr>
<tr>
<td>Not Eligible for HAART</td>
<td>3 (0.80)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>2 (0.54)</td>
<td>1 (0.27)</td>
<td>6 (1.61)</td>
</tr>
<tr>
<td>Eligibility Unknown</td>
<td>0 (0.00)</td>
<td>2 (0.54)</td>
<td>1 (0.27)</td>
<td>11 (2.95)</td>
<td>12 (3.22)</td>
<td>26 (6.97)</td>
</tr>
<tr>
<td>Total</td>
<td>22 (5.90)</td>
<td>41 (11.00)</td>
<td>42 (11.26)</td>
<td>132 (35.39)</td>
<td>136 (36.46)</td>
<td>373 (100.00)</td>
</tr>
<tr>
<td><strong>Adherence &gt;96%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>7 (1.88)</td>
<td>38 (10.19)</td>
<td>25 (6.70)</td>
<td>70 (18.77)</td>
</tr>
<tr>
<td>No</td>
<td>22 (5.90)</td>
<td>41 (11.00)</td>
<td>35 (9.38)</td>
<td>94 (25.20)</td>
<td>111 (29.76)</td>
<td>303 (81.23)</td>
</tr>
<tr>
<td>Total</td>
<td>22 (5.90)</td>
<td>41 (11.00)</td>
<td>42 (11.26)</td>
<td>132 (35.39)</td>
<td>136 (36.46)</td>
<td>373 (100.00)</td>
</tr>
</tbody>
</table>

The conduction of the two tests (Markson and Umoh, 2013).

**Evaluation of the clinical outcome (HIV status of the children)**

The measure of this outcome is the percentage of the children that tested positive to the HIV DNA-PCR and HIV Antibody tests, hence enrolled into HAART after PMTCT.

The result of this study indicated that PMTCT was able to prevent the transmission of HIV from mother to child in 359 (97.80%) of the cases. The percentage of infected infants (2.18%) is less than the 4% transmission rate discovered from a one year study at a secondary healthcare centre in Akwa Ibom State, Nigeria (Markson and Umoh, 2013). It also falls within the international target of lower than 5% reduction of mother-to-child transmission of HIV (UNICEF, 2012). A meta-analysis of the effectiveness of PMTCT in sub-Saharan Africa showed that 7.1% (for a two-drug regimen) and 4.04% (for a three-drug regimen) of
Table 2. ART Regimen used for the pregnant women at APIN-CDC Clinic UNTH Enugu (2008-2012)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency (percentage)</td>
<td>16 (4.29)</td>
<td>30 (8.04)</td>
<td>33 (8.85)</td>
<td>109 (29.22)</td>
<td>112 (30.03)</td>
<td>300 (80.43)</td>
</tr>
<tr>
<td>ART Regimen used for PMTCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZT/3TC/NVP</td>
<td>TDF/3TC + NVP</td>
<td>TDF/3TC + AZT + LPV/r</td>
<td>TDF/3TC + NVP +LPV/r</td>
<td>3TC + ABC + NVP</td>
<td>TDF/3TC + EFV</td>
<td>3TC/AZT</td>
</tr>
<tr>
<td>2008</td>
<td>1 (0.27)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
</tr>
<tr>
<td>2009</td>
<td>4 (1.07)</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
<td>1 (0.27)</td>
<td>1 (0.27)</td>
<td>5 (1.35)</td>
</tr>
<tr>
<td>2010</td>
<td>5 (1.35)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
<td>5 (1.35)</td>
</tr>
<tr>
<td>2011</td>
<td>14 (3.75)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
</tr>
<tr>
<td>2012</td>
<td>109 (29.22)</td>
<td>581 (15.03)</td>
<td>17 (4.65)</td>
<td>16 (4.29)</td>
<td>17 (4.65)</td>
<td>16 (4.29)</td>
</tr>
<tr>
<td>Total</td>
<td>300 (80.43)</td>
<td>300 (80.43)</td>
<td>300 (80.43)</td>
<td>300 (80.43)</td>
<td>300 (80.43)</td>
<td>300 (80.43)</td>
</tr>
</tbody>
</table>

Table 3. ART regimen used for the pregnant women based on their Pre-PMTCT Status at APIN-CDC Clinic UNTH Enugu (2008-2012).

<table>
<thead>
<tr>
<th>ART regimen used for PMTCT</th>
<th>Woman already on HAART</th>
<th>Woman commencing HAART</th>
<th>Woman not eligible for HAART</th>
<th>Not Indicated</th>
<th>Total</th>
<th>$\chi^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency (Percentage)</td>
<td>272 (72.92)</td>
<td>13 (3.49)</td>
<td>0 (0.00)</td>
<td>15 (4.02)</td>
<td>300 (80.43)</td>
<td>0.00*</td>
</tr>
<tr>
<td>AZT/3TC/NVP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TDF/3TC + NVP</td>
<td>36 (9.65)</td>
<td>1 (0.27)</td>
<td>0 (0.00)</td>
<td>4 (1.07)</td>
<td>41 (11.00)</td>
<td>0.00*</td>
</tr>
<tr>
<td>TDF/3TC + AZT + LPV/r</td>
<td>3 (0.80)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>3 (0.80)</td>
<td>6 (1.61)</td>
<td>0.00*</td>
</tr>
<tr>
<td>TDF/3TC + NVP + LPV/r</td>
<td>1 (0.27)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
<td>0.00*</td>
</tr>
<tr>
<td>3TC + ABC + NVP</td>
<td>3 (0.80)</td>
<td>1 (0.27)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>4 (1.07)</td>
<td>0.00*</td>
</tr>
<tr>
<td>AZT/3TC + EFV</td>
<td>3 (0.80)</td>
<td>4 (1.07)</td>
<td>0 (0.00)</td>
<td>4 (1.07)</td>
<td>11 (2.95)</td>
<td>0.00*</td>
</tr>
<tr>
<td>3TC/AZT</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>6 (1.61)</td>
<td>0 (0.00)</td>
<td>6 (1.61)</td>
<td>0.00*</td>
</tr>
<tr>
<td>TDF/FTC/EFV</td>
<td>2 (0.54)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>2 (0.54)</td>
<td>0.00*</td>
</tr>
<tr>
<td>TDF/3TC + ATV/r + RTV</td>
<td>1 (0.27)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
<td>0.00*</td>
</tr>
<tr>
<td>TDF/3TC + EFV</td>
<td>1 (0.27)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>1 (0.27)</td>
<td>0.00*</td>
</tr>
<tr>
<td>Total</td>
<td>322 (86.32)</td>
<td>19 (5.09)</td>
<td>6 (1.61)</td>
<td>26 (6.97)</td>
<td>373 (100.00)</td>
<td>0.00*</td>
</tr>
</tbody>
</table>

*Significant at p<0.05
Table 4. The PMTCT properties of the exposed children at APIN-CDC Clinic UNTH Enugu (2008-2012).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency</td>
<td>Percentage</td>
<td>Frequency</td>
<td>Percentage</td>
<td>Frequency</td>
<td>Percentage</td>
</tr>
<tr>
<td>Received recommended ART</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>9 (2.45)</td>
<td>74 (20.16)</td>
<td>120 (32.70)</td>
<td>164 (44.69)</td>
<td>367 (100.00)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>9 (2.45)</td>
<td>74 (20.16)</td>
<td>120 (32.70)</td>
<td>164 (44.69)</td>
<td>367 (100.00)</td>
<td></td>
</tr>
<tr>
<td>ARV used</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZT</td>
<td>9 (2.45)</td>
<td>49 (13.35)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>58 (15.80)</td>
<td></td>
</tr>
<tr>
<td>NVP</td>
<td>0 (0.00)</td>
<td>25 (6.81)</td>
<td>120 (32.70)</td>
<td>164 (44.69)</td>
<td>309 (84.20)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>9 (2.45)</td>
<td>74 (20.16)</td>
<td>120 (32.70)</td>
<td>164 (44.69)</td>
<td>367 (100.00)</td>
<td></td>
</tr>
<tr>
<td>HIV DNA-PCR result</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>0 (0.00)</td>
<td>4 (1.09)</td>
<td>3 (0.82)</td>
<td>1 (0.27)</td>
<td>8 (2.18)</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>9 (2.45)</td>
<td>70 (19.07)</td>
<td>117 (31.88)</td>
<td>163 (44.41)</td>
<td>359 (97.80)</td>
<td></td>
</tr>
<tr>
<td>Not Conducted</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>9 (2.45)</td>
<td>74 (20.16)</td>
<td>120 (32.70)</td>
<td>164 (44.69)</td>
<td>367 (100.00)</td>
<td></td>
</tr>
<tr>
<td>HIV Antibody test result</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td></td>
</tr>
<tr>
<td>Not Conducted</td>
<td>9 (2.45)</td>
<td>74 (20.16)</td>
<td>120 (32.70)</td>
<td>164 (44.69)</td>
<td>367 (100.00)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>9 (2.45)</td>
<td>74 (20.16)</td>
<td>120 (32.70)</td>
<td>164 (44.69)</td>
<td>367 (100.00)</td>
<td></td>
</tr>
</tbody>
</table>

the infants tested positive to HIV (Adane, 2012). A study in Kenya even produced 9% HIV-positive infants after 18 months post-delivery (Odhiambo et al., 2013).

Conclusion

APIN-CDC Clinic UNTH Enugu substantially implemented the WHO and FMOH guidelines in its PMTCT services. The result of the clinical outcome evaluation showed that the percentage of transmission of HIV from mother to child among its PMTCT enrollees is below all local and international targets, as well as results from other studies.

RECOMMENDATIONS

Although the findings of the study showed a good clinical outcome, it is still recommended that the clinic incorporates other aspects of PMTCT for a comprehensive coverage. It is also recommended that the center introduces the conduction of tests for the infants immediately after birth.

Conflict of interest

The authors have not declared any conflict of interest.

ACKNOWLEDGEMENT

APIN (PS 001058) with support from the US Department of Health and Human Services, Health Resources and Services Administration (U51HA02522) and the Centers for Disease Control and Prevention (CDC) provided treatment and care and managed the database for the patients whose data were used for this study. That role forms the crux of this study and is hereby appreciated.

REFERENCES

Adane D (2012). Effectiveness of PMTCT programs in Sub-Saharan Africa, a meta-analysis; a thesis presented in partial fulfillment of the requirements for the degree of Master of Science with specialty in Epidemiology; Umeå International School of Public Health, Umeå.


